ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. - Wikidata - wikimedia - TriplyDB

ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.

ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.

http://www.wikidata.org/entity/Q40379188

about

Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines Glycomic Approaches for the Discovery of Targets in Gastrointestinal Cancer Hallmarks of glycosylation in cancer Challenges in Antibody Development against Tn and Sialyl-Tn Antigens Galectin-Binding O-Glycosylations as Regulators of Malignancy Regulation of the metastatic cell phenotype by sialylated glycans Intra- and Extra-Cellular Events Related to Altered Glycosylation of MUC1 Promote Chronic Inflammation, Tumor Progression, Invasion, and Metastasis The Role of Sialyl-Tn in Cancer Advancement of Sialyltransferase Inhibitors: Therapeutic Challenges and Opportunities Sialyl-tn in cancer: (how) did we miss the target?Tumour-associated carbohydrate antigens in breast cancer.Over-expression of ST3Gal-I promotes mammary tumorigenesis.Increased expression of sialic acid in cervical biopsies with squamous intraepithelial lesions Suppression of core 1 Gal-transferase is associated with reduction of TF and reciprocal increase of Tn, sialyl-Tn and Core 3 glycans in human colon cancer cells Primary breast cancer tumours contain high amounts of IgA1 immunoglobulin: an immunohistochemical analysis of a possible carrier of the tumour-associated Tn antigen.Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killing.Aberrant glycosylation associated with enzymes as cancer biomarkers.Single molecule study of heterotypic interactions between mucins possessing the Tn cancer antigen.Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model.Glycosyltransferases as Markers for Early Tumorigenesis.Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.Loss of Core 1-derived O-Glycans Decreases Breast Cancer Development in Mice A Novel Variant in CMAH Is Associated with Blood Type AB in Ragdoll Cats.IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1 Interactions between the breast cancer-associated MUC1 mucins and C-type lectin characterized by optical tweezers.Protein glycosylation in diverse cell systems: implications for modification and analysis of recombinant proteins.Nuclear repartitioning of galectin-1 by an extracellular glycan switch regulates mammary morphogenesis Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy Preferential lectin binding of cancer cells upon sialic acid treatment under nutrient deprivation Variation in Carbohydrates between Cancer and Normal Cell Membranes Revealed by Super-Resolution Fluorescence Imaging.Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches.Modification of sialylation mediates the invasive properties and chemosensitivity of human hepatocellular carcinoma.Altered tumor-cell glycosylation promotes metastasis.Functional roles of sialylation in breast cancer progression through miR-26a/26b targeting ST8SIA4.Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension.O-glycan sialylation alters galectin-3 subcellular localization and decreases chemotherapy sensitivity in gastric cancer.MUC1 immunotherapy.The Tn antigen-structural simplicity and biological complexity.The Cosmc connection to the Tn antigen in cancer.The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer.

P2860

Q26740513-760486E4-E7CE-4A88-BD44-26E7FA129F43 Q26750872-D949F22C-4318-4E1A-8AD5-1BC9B120A539 Q26752363-D0479A89-543A-4C70-B4CD-7019F6D6B4E4 Q26798183-AD961EC0-7503-4410-8C4A-75DC9D4F0053 Q26801724-F960752D-1EB0-4DC9-9D85-ADA6C85E7BCA Q27027559-DE35D5E9-3E34-4714-8404-326F6896F551 Q28066445-E1B2974E-43E5-485C-8069-D666270ADE63 Q28075448-C230D301-8CD2-475E-BE91-E960A68F4B84 Q30039640-29FE0812-5B60-4F80-AE1B-06B69D8F8C32 Q33649572-DF730056-7391-4E52-9164-E4FB2E7C9BCD Q34048052-275188D1-78BC-44E5-8727-EDF73D81BE0E Q34107518-60272C36-B478-4CA1-82D7-4FBFAC6A12C3 Q34380061-2ABEA4D7-5A29-4088-B501-5E9E6D6DFFBC Q34639786-00FDBE09-226B-415B-8716-E89A39C1EDE8 Q34700620-40EAE7BF-513D-428E-85E8-086984789FCD Q34988382-FCB46656-7C87-41B5-8340-D5BE74879EB3 Q35206309-798CD5D6-828A-47C3-A182-282FB0FB03CF Q35216220-C01C59F3-41DB-49A4-B65B-4C454C320F3A Q35745593-5BBA8801-129E-48D2-BE90-9C6F6C74C152 Q35802482-991FAFF5-C5A1-43D0-B3FC-A986EB7F498A Q35841848-87B7041E-376E-439B-A798-0AC699391FB5 Q35953085-27AAF991-53C6-4EAE-8BBF-191FFA092FFE Q36015713-D148D55F-8DDE-4D83-8229-72CD175924D1 Q36303703-4BC32C94-5DCD-4591-8EB8-DCF302EF347C Q36348610-6AEB6CFC-C033-4144-9B97-1B411CEB3A66 Q36505675-56E85212-DDC1-43AA-AAE0-52574F45C812 Q37199993-3FAA77BB-D263-4760-A462-E0AB64468B0F Q37235573-56315D00-9E92-42E1-BFC6-B1C8EA5F0E94 Q37269017-D395FA2B-E4E6-4148-81B9-C695F0280698 Q37505096-4B46F8A8-B5BA-4D33-AD20-E545176B4DEA Q37512647-3B1E107B-5234-4E77-AC60-F9F3F06674ED Q37563910-652465A6-BAE4-4F77-A1DA-DE7142F696F4 Q37581540-2F6DF2DD-64B4-4C68-8707-9B04410E4D90 Q37603425-0417EB9D-810A-4EF9-BEF4-02803CEF75C4 Q37665276-12F2CE0D-3035-4CE9-8DEE-E53C215472AD Q37696344-9B7EA33E-3E2D-489A-8AAE-F56BC59E0560 Q37773241-F73FD5D6-BED8-4CEE-A107-347EFB76B89F Q37831859-BFC52EF4-6AFC-43FA-9791-A977ACC8A70B Q38197051-6323DE87-BE6C-4C23-ABDB-B9DF587FFB7B Q38259961-E6523242-8CE0-455A-BCE1-5D430A0CE822

P2860

ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.

http://www.wikidata.org/entity/Q40379188

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

ST6GalNAc I expression in MDA- ...... nhances their tumourigenicity.

@en

type

label

ST6GalNAc I expression in MDA- ...... nhances their tumourigenicity.

@en

prefLabel

ST6GalNAc I expression in MDA- ...... nhances their tumourigenicity.

@en

P1433

Q40379188-7B1824EC-F1EB-4413-AF2C-CF557C483921

P1476

Q40379188-FB8DFCE0-BEA4-4EB1-A998-1DA2BEB53DBC

P2093

Q40379188-123DF23E-BF53-478E-8405-5FF711D1C786

Q40379188-1C252B4D-55E4-4DF7-AD75-DF449A89C99D

Q40379188-4BA1637C-29B0-4893-AD98-D83E7AFB47B3

Q40379188-5BE10D44-54B6-4FF5-A8CC-7E8E7792D675

Q40379188-BFDA5296-9071-4F1B-B687-AD32072F7ABE

Q40379188-E67AC593-676D-4521-9D68-37DD99C65C02

P2860

Q40379188-0EFA1AF8-EC3E-4D0C-A579-7603C3D41BF7

Q40379188-1954C3DE-45B5-41C1-8CC5-4C4345FDB41F

Q40379188-1DF4B8DA-DE64-41DA-82F4-0C2A59C898A3

Q40379188-1EB9AA4A-6A1F-4AD9-804F-CCC732D4291F

Q40379188-3A896922-DE7D-42AA-994D-5CB1FB35AEB9

Q40379188-3F8DE310-9A03-4745-8B99-F5CC28BDAB4F

Q40379188-43AE4DCE-3A04-4B00-A962-C899682B832F

Q40379188-4A015B69-07A3-4A44-BE76-6DF5238594EB

Q40379188-55F74F35-8756-48A7-9DD6-885E1BCB33DC

Q40379188-5FF4FA36-E003-4ADB-A37B-EB670A01F02D

P304

Q40379188-294844C6-A3FD-438F-886D-EA9B5CB772BF

P31

Q40379188-145CBA43-5FED-4AD4-87C2-38034B15207C

P356

Q40379188-A5FB752F-DA2B-4B32-B996-214C31936915

P433

Q40379188-8312E142-7824-40B2-B257-6C030849B4CD

P478

Q40379188-D5A12259-7BE3-416E-BF9E-DFF93A5B6957

P50

Q40379188-72616E58-A8A5-43FC-BF67-868787C9FD77

Q40379188-D8B4786C-A091-400F-B9A0-360439C5737B

Q40379188-FB12DBA4-A0C2-4D69-9139-C001C9EC6307

P577

Q40379188-0E4F5C16-30A2-4C1D-85AE-2A7A4E4C07B5

P5875

Q40379188-D67081A3-4B66-4BC7-90CC-056BDCBDEB5E

P698

Q40379188-E14823B5-8030-4693-A987-8558BD364064

P921

Q40379188-F3059F3C-CC07-45FC-94E9-F811ECCA9E8D

P356

P1433

P1476

ST6GalNAc I expression in MDA- ...... enhances their tumourigenicity

@en

P2093

Adriaenssens E

http://www.w3.org/2001/XMLSchema#string

Courtand G

http://www.w3.org/2001/XMLSchema#string

Hanisch FG

http://www.w3.org/2001/XMLSchema#string

Julien S

http://www.w3.org/2001/XMLSchema#string

Le Bourhis X

http://www.w3.org/2001/XMLSchema#string

Ottenberg K

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and expression of a human gene encoding an N-acetylgalactosamine-alpha2,6-sialyltransferase (ST6GalNAc I): a candidate for synthesis of cancer-associated sialyl-Tn antigens

Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. High density and prevalent core 2-based glycosylation.

Structural analysis of permethylated oligosaccharides using electrospray ionization quadrupole time-of-flight tandem mass spectrometry and deutero-reduction.

The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1.

Adhesion proteins in the biology of breast cancer: contribution of CD44.

Inhibition of mucin glycosylation.

Cell surface-expressed Thomsen-Friedenreich antigen in colon cancer is predominantly carried on high molecular weight splice variants of CD44.

Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA.

Inhibition of the glycosylation and alteration in the intracellular trafficking of mucins and other glycoproteins by GalNAcalpha-O-bn in mucosal cell lines: an effect mediated through the intracellular synthesis of complex GalNAcalpha-O-bn oligosacc

Nonselective and efficient fluorescent labeling of glycans using 2-amino benzamide and anthranilic acid.

P304

54-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/GLYCOB/CWJ033

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Philippe Delannoy

Alessandro Furlan

Anne-Sophie Vercoutter-Edouart

P577

2005-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7624767

http://www.w3.org/2001/XMLSchema#string

P698

16135558

http://www.w3.org/2001/XMLSchema#string

P921